Phenotypes and outcome of diffuse pulmonary non-amyloid light chain deposition disease.
Bronchiectasis
Light chain deposition disease
Lung cysts
Lung transplantation
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
10 Apr 2024
10 Apr 2024
Historique:
received:
18
10
2023
accepted:
01
04
2024
medline:
11
4
2024
pubmed:
11
4
2024
entrez:
10
4
2024
Statut:
epublish
Résumé
Light chain deposition disease (LCDD) is a very rare entity. Clinical manifestations of LCDD vary according to the organs involved. Data on pulmonary LCDD are scarce and limited to small series or case reports. This study aimed to describe the characteristics and outcome of diffuse pulmonary non-amyloid LCDD localized to the lungs. A multicenter retrospective cohort study was conducted. Clinical characteristics were collected, and chest CTs were centrally reviewed. The diagnosis of pulmonary non-amyloid LCDD was confirmed by immunohistochemistry. Thirty-one cases were identified (68% female), with a median age at diagnosis of 50 years (IQR 20). Baseline FEV1/FVC was < 0.70 in 45% of patients. Mean (± SD) FEV1 and DLCO were 86% ± 26.2 and 52% ± 23.9, respectively. CT revealed peculiar patterns of thin-walled cysts (58%) and thin-walled cystic bronchiectases (27%). Increased serum kappa light chain was found in 87% of patients. Histological analysis showed kappa light chain deposits in all patients, except one with lambda chain deposits. Median annual FEV1 decline was 127 ml (IQR 178) and median DLCO decline was 4.3% (IQR 4.3). Sixteen patients received immunomodulatory treatment or chemotherapy; serum light chain levels decreased in 9 cases (75%), without significant improvement in FEV1 (p = 0.173). Overall, 48% of patients underwent bilateral lung transplantation. Transplant-free survival at 5 and 10 years were 70% and 30%, respectively. An annual FEV1 decline greater than 127 ml/year was associated with increased risk of death or transplantation (p = 0.005). Diffuse pulmonary LCDD is characterised by female predominance, a peculiar imaging pattern with bronchiectasis and/or cysts, progressive airway obstruction and severe DLCO impairment, and poor outcome. Lung transplantation is a treatment of choice.
Sections du résumé
BACKGROUND
BACKGROUND
Light chain deposition disease (LCDD) is a very rare entity. Clinical manifestations of LCDD vary according to the organs involved. Data on pulmonary LCDD are scarce and limited to small series or case reports. This study aimed to describe the characteristics and outcome of diffuse pulmonary non-amyloid LCDD localized to the lungs.
STUDY DESIGN AND METHODS
METHODS
A multicenter retrospective cohort study was conducted. Clinical characteristics were collected, and chest CTs were centrally reviewed. The diagnosis of pulmonary non-amyloid LCDD was confirmed by immunohistochemistry.
RESULTS
RESULTS
Thirty-one cases were identified (68% female), with a median age at diagnosis of 50 years (IQR 20). Baseline FEV1/FVC was < 0.70 in 45% of patients. Mean (± SD) FEV1 and DLCO were 86% ± 26.2 and 52% ± 23.9, respectively. CT revealed peculiar patterns of thin-walled cysts (58%) and thin-walled cystic bronchiectases (27%). Increased serum kappa light chain was found in 87% of patients. Histological analysis showed kappa light chain deposits in all patients, except one with lambda chain deposits. Median annual FEV1 decline was 127 ml (IQR 178) and median DLCO decline was 4.3% (IQR 4.3). Sixteen patients received immunomodulatory treatment or chemotherapy; serum light chain levels decreased in 9 cases (75%), without significant improvement in FEV1 (p = 0.173). Overall, 48% of patients underwent bilateral lung transplantation. Transplant-free survival at 5 and 10 years were 70% and 30%, respectively. An annual FEV1 decline greater than 127 ml/year was associated with increased risk of death or transplantation (p = 0.005).
CONCLUSIONS
CONCLUSIONS
Diffuse pulmonary LCDD is characterised by female predominance, a peculiar imaging pattern with bronchiectasis and/or cysts, progressive airway obstruction and severe DLCO impairment, and poor outcome. Lung transplantation is a treatment of choice.
Identifiants
pubmed: 38600600
doi: 10.1186/s12931-024-02798-y
pii: 10.1186/s12931-024-02798-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
159Investigateurs
Yurdagül Uzunhan
(Y)
Stéphane Jouneau
(S)
Informations de copyright
© 2024. The Author(s).
Références
Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology and molecular analysis. Ann Intern Med. 1990;112:455–64.
doi: 10.7326/0003-4819-76-3-112-6-455
pubmed: 2106817
Randall RE, Williamson WC, Mullinax F, Tung MY, Still WJ. Manifestations of systemic light chain deposition. Am J Med. 1976;60:293–9.
doi: 10.1016/0002-9343(76)90440-X
pubmed: 814812
Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light-and heavy-chain deposition diseases. Hematol Oncol Clin North Am. 1999;13:1235–48.
doi: 10.1016/S0889-8588(05)70123-4
pubmed: 10626147
Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D’Agati VD. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12:1482–92.
doi: 10.1681/ASN.V1271482
pubmed: 11423577
Colombat M, Holifanjaniaina S, Guillonneau F, Mal H, Hirschi S, Reynaud-Gaubert M, Stern M. Mass spectrometry-based proteomic analysis: a good diagnostic tool for cystic lung light chain deposition disease. Am J Respir Crit Care Med. 2013;188:404–5.
doi: 10.1164/rccm.201301-0071LE
pubmed: 23905535
Kijner CH, Yousem SA. Systemic light chain deposition disease presenting as multiple pulmonary nodules. A case report and review of the literature. Am J Surg Pathol. 1988;12:405–13.
doi: 10.1097/00000478-198805000-00009
pubmed: 3129952
Khoor A, Myers JL, Tazelaar HD, Kurtin PJ. Amyloid-like pulmonary nodules, including localized light-chain deposition: clinicopathologic analysis of three cases. Am J Clin Pathol. 2004;121:200–4.
doi: 10.1309/3GECPW2402F6V8EK
pubmed: 14983932
Mezzanotte JN, Gibbons-Fideler IS, Shilo K, Lustberg M, Devarakonda S. Nodular pulmonary deposition disease in a patient with the acquired immunodeficiency syndrome: a case report. J Med Case Rep. 2020;14:64.
doi: 10.1186/s13256-020-02394-w
pubmed: 32498712
pmcid: 7273682
Miró O, Fernández-Solá J, Gómez-Angelats E, Andreu MV, Solé M. [Tracheobronchomegaly associated with light chain deposition disease]. Arch Bronconeumol. 1994;30:508–10.
doi: 10.1016/S0300-2896(15)31003-6
pubmed: 7827766
Colombat M, Gounant V, Mal H, Callard P, Milleron B. Light chain deposition disease involving the airways: diagnosis by fibreoptic bonchoscopy. Eur Respir J. 2007;29:1057–60.
doi: 10.1183/09031936.00134406
pubmed: 17470625
Girard N, Vasiljevic A, Cottin V, Falchero L, Meyronet D, Thivolet-Bejui F, Cordier JF. Respiratory failure with diffuse bronchiectases and cryoglobulinaemia. Eur Respir J. 2008;31:1374–8.
doi: 10.1183/09031936.00004408
pubmed: 18515561
Colombat M, Caudroy S, Lagonotte E, Mal H, Danel C, Stern M, Fournier M, Birembaut P. Pathomechanisms of cyst formation in pulmonary light chain deposition disease. Eur Respir J. 2008;32:1399–403.
doi: 10.1183/09031936.00132007
pubmed: 18978139
Kato T, Muto H, Hishima T, Kawashima M, Nagai H, Matsui H, Shimada M, Hebisawa A, Doki N, Miyawaki S, Ohashi K. A 56-Year-old woman with multiple pulmonary cysts and severe chest Pain. Chest. 2018;153:e105–12.
doi: 10.1016/j.chest.2017.12.002
pubmed: 29731050
Colombat M, Stern M, Groussard O, Droz D, Brauner M, Valeyre D, Mal H, Taille C, Monnet I, Fournier M, Herson S, Danel C. Pulmonary cystic disorder related to light chain deposition disease. Am J Respir Crit Care Med. 2006;173:777–80.
doi: 10.1164/rccm.200510-1620CR
pubmed: 16399989
Gorospe Sarasúa L, Pacios-Blanco RE, Arrieta P, Chinea-Rodríguez A. Intracystic hemorrhage in a patient with pulmonary cystic disorder related to light-chain deposition disease. Arch Bronconeumol. 2017;53:285–7.
doi: 10.1016/j.arbres.2016.08.008
pubmed: 27756655
Borgne AL, Prévot G, Rouquette I, Huynh A, Têtu L, Projetti F, Carreiro M, Borie R, Jaccard A, Recher C, Didier A. Blood stem cell transplantation to treat cystic lung light chain deposition disease. Eur Respir J. 2015;46:1199–202.
doi: 10.1183/13993003.00577-2014
pubmed: 26160867
Hirschi S, Colombat M, Kessler R, Reynaud-Gaubert M, Stern M, Chenard MP, Métivier AC, Jeung MY, Mal H. Lung transplantation for advanced cystic lung disease due to nonamyloid kappa light chain deposits. Ann Am Thorac Soc. 2014;11:1025–31.
doi: 10.1513/AnnalsATS.201404-137OC
pubmed: 25118847
Delaey P, Plawny L, Nchimi A, Hirschi S, Weingertner N, Santelmo N, Wirtz G. [Effect of surgery of pulmonary cysts related to immunoglobulin light chain deposits]. Rev Mal Respir. 2020;37:180–6.
doi: 10.1016/j.rmr.2020.01.001
pubmed: 32014310
Camus M, Hirschi S, Prevot G, Chenard MP, Mal H, Stern M, Reynaud-Gaubert M, Gilhodes J, Burlet-Schiltz O, Brousset P, Colombat M. Proteomic evidence of specific IGKV1-8 association with cystic lung light chain deposition disease. Blood. 2019;133:2741–4.
doi: 10.1182/blood.2019898577
pubmed: 30967366
Gibier JB, Perbet R, Lopez B, Colombat M, Dubois R, Humez S, Terriou L, Copin MC, Gnemmi V. Paraffin immunofluorescence increases light-chain detection in Extra-renal Light Chain Amyloidosis and other Light-Chain-Associated diseases. Arch Pathol Lab Med. 2021;145:352–8.
doi: 10.5858/arpa.2020-0018-OA
pubmed: 32539437
Colombat M, Mal H, Copie-Bergman C, Diebold J, Damotte D, Callard P, Fournier M, Farcet JP, Stern M, fau-Larue MH. Primary cystic lung light chain deposition disease: a clinicopathologic entity derived from unmutated B cells with a stereotyped IGHV4-34/IGKV1 receptor. Blood. 2008;112:2004–12.
doi: 10.1182/blood-2007-11-123596
pubmed: 18483396
Baqir M, Moua T, White D, Yi ES, Ryu JH. Pulmonary nodular and cystic light chain deposition disease: a retrospective review of 10 cases. Respir Med. 2020;164:105896.
doi: 10.1016/j.rmed.2020.105896
pubmed: 32217287
Wei P, Tao R, Liu Y, Xie H, Jiang S, Yu D, Lu H, Cao W. Pulmonary light chain deposition disease: a case series and literature review. Annals Transl Med. 2020;8:588.
doi: 10.21037/atm-20-2708
Arrossi AV, Merzianu M, Farver C, Yuan C, Wang SH, Nakashima MO, Cotta CV. Nodular pulmonary light chain deposition disease: an entity associated with Sjögren syndrome or marginal zone lymphoma. J Clin Pathol. 2016;69:490–6.
doi: 10.1136/jclinpath-2015-203342
pubmed: 26502747
Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G. The lung in amyloidosis. Eur Respir Rev. 2017;26:170046.
doi: 10.1183/16000617.0046-2017
pubmed: 28877975
pmcid: 9488920
Sheard S, Nicholson AG, Edmunds L, Wotherspoon AC, Hansell DM. Pulmonary light-chain deposition disease: CT and pathology findings in nine patients. Clin Radiol. 2015;70:515–22.
doi: 10.1016/j.crad.2015.01.002
pubmed: 25659938
Park HJ, Chae EJ, Do KH, Lee SM, Song JW. Differentiation between Lymphangioleiomyomatosis and Birt-Hogg-Dubé Syndrome: analysis of pulmonary cysts on CT images. AJR Am J Roentgenol. 2019;212:766–72.
doi: 10.2214/AJR.18.20232
pubmed: 30673341
Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, Merlini G. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132:1478–85.
doi: 10.1182/blood-2018-04-839480
pubmed: 30012636
Clayden RC, Macdonald D, Oikonomou A, Cheung MC. Cystic lung disease with kappa light chain deposition in newly diagnosed multiple myeloma. Br J Haematol. 2020;188:201.
doi: 10.1111/bjh.16236
pubmed: 31625161
Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365:1184–92.
doi: 10.1056/NEJMoa1105482
pubmed: 21991892
Daccord C, Cottin V, Prévot G, Uzunhan Y, Mornex JF, Bonniaud P, Borie R, Briault A, Collonge-Rame MA, Crestani B, Devouassoux G, Freynet O, Gondouin A, Hauss PA, Khouatra C, Leroy S, Marchand-Adam S, Marquette C, Montani D, Naccache JM, Nadeau G, Poulalhon N, Reynaud-Gaubert M, Salaun M, Wallaert B, Cordier JF, Faouzi M, Lazor R. Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patients. Orphanet J Rare Dis. 2020;15:120.
doi: 10.1186/s13023-020-01402-y
pubmed: 32448321
pmcid: 7245949
Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest. 2004;126:1867–74.
doi: 10.1378/chest.126.6.1867
pubmed: 15596686
Tazi A, de Margerie C, Naccache JM, Fry S, Dominique S, Jouneau S, Lorillon G, Bugnet E, Chiron R, Wallaert B, Valeyre D, Chevret S. The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis. 2015;10:30.
doi: 10.1186/s13023-015-0249-2
pubmed: 25887097
pmcid: 4438520
Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis. 1992;20:34–41.
doi: 10.1016/S0272-6386(12)80314-3
pubmed: 1621676
Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Brouet JC, Fermand JP. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int. 2004;65:642–8.
doi: 10.1111/j.1523-1755.2004.00427.x
pubmed: 14717936
Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis. 2004;43:147–53.
doi: 10.1053/j.ajkd.2003.09.020
pubmed: 14712438
Aimo A, Vergaro G, Pucci A, Bernazzali S, Maccherini M, Buda G, Passino C, Merlini G, Emdin M. Cardiac light-chain deposition disease relapsing in the transplanted heart. Amyloid. 2017;24:135–7. OrphaLung network (collaborators) 19 Yurdagül UZUNHAN, Avicenne hospital, APHP, Paris Nord university, Paris, France 20 Stéphane JOUNEAU, Pontchaillou Hospital, Rennes, France.
doi: 10.1080/13506129.2017.1334196
pubmed: 28562083